

References

Acevedo-Garcia, D., *Children Left Behind: How Metropolitan Areas are Failing America's Children*. Jan 2007. http://diversitydata-archive.org/Downloads/children_left_behind_final_report.pdf.

ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management Pediatrics 2011;128;1007, 2011-2654.

Agency for Healthcare Research (AHRQ). Background Report for the Request for Public Comment on Initial, Recommended Core Set of Children's Healthcare Quality Measures for Voluntary Use by Medicaid and CHIP Programs. Table 1. Initial, recommended set of children's health care quality measures. Rockville (MD); 2010 Jan.

American Academy of Pediatrics, Steering Committee on Quality Improvement. Classifying recommendations for clinical practice guidelines. *Pediatrics*. 2004;114(3):874-877.

American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2011;128(5):1007-1022.

Anderson LM, Scrimshaw SC, Fullilove MT, Fielding JE, Normand J. Culturally Competent Healthcare Systems: A Systematic Review. *Am J Prev Med*; 24(3):68-79 Supp, Apr 2003.

Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-risk Preschoolers; Long-term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. *In Press*.

Avigan M. *Review of AERS Data from Marketed Safety Experience During Stimulant Therapy: Death, Sudden Death, Cardiovascular SAEs (Including Stroke)*. Report No. D030403. Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004.

Avigan M. *Review of AERS Data from Marketed Safety Experience During Stimulant Therapy: Death, Sudden Death, Cardiovascular SAEs (Including Stroke)*. Report No. D030403. Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004.

Bailey RK, Ali S, Jabeen S, et al. Attention-deficit/hyperactivity disorder in African American youth. *Curr Psychiatry Rep* 2010;125:396-402.

Braveman, PA. Monitoring Equity in Health and Healthcare: A Conceptual Framework. *J Health Popul Nutr*; 2003: Sep;21(3):181-192.

Bussing, et al; Use and persistence of pharmacotherapy for elementary school students with ADHD; *J Child Adolesc Psychopharmacol* 2005 Feb;15(1):78-87]

Centers for Disease Control and Prevention (CDC), *Vital and Health Statistics* (December 2010; Series 10, Number 247).

Egger HL, Kondo D, Angold A. The epidemiology and diagnostic issues in preschool attention-deficit/hyperactivity disorder. *Infant Young Child*. 2006;19(2):109-122

Froehlich T E, Lanphear B P, Epstein J N, et al. Prevalence, Recognition, and Treatment of Attention-Deficit/Hyperactivity Disorder in a National Sample of US Children. *Arch Pediatr Adolesc Med*. 2007;161(9):857-864.

Gadow KD, Nolan EE, Litcher L, et al. Comparison of attention-deficit/hyperactivity disorder symptoms subtypes in Ukrainian schoolchildren. *J Am Acad Child Adolesc Psychiatry*. 2000;39(12):1520-1527.

Gardner W, Kelleher K J, Pajer K. Follow-up Care of Children Identified with ADHD by Primary Care Clinicians: A Prospective Cohort Study. *J Peds*. December 2004.

Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. *Am J Psychiatry*. 2009;166(9):992-1001.

Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry*. 2006;45(11):1284-1293.

Harvey EA, Youngwirth SD, Thakar DA, Errazuriz PA. Predicting attention-deficit/hyperactivity disorder and oppositional defiant disorder from preschool diagnostic assessments. *J Consult Clin Psychol*. 2009;77(2):349-354

Hoagwood K, et al. Changes in ADHD Treatment Services: Treatment Services for Children with ADHD: A National Perspective, *J. Am Acad Child Adolesc Psych* 2000, 39(2):198-206.

http://healthit.hhs.gov/portal/server.pt/community/healthit_hhs_gov__standards_ifr/1195).

<http://www.iom.edu/~media/Files/Report%20Files/2009/RaceEthnicityData/Race%20Ethnicity%20report%20brief%20FINAL%20for%20web.pdf>.

Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2010 Mar;72.

Janet Currie, et al. Policy Interventions to Address Child Health Disparities: Moving Beyond Health Insurance. *J Amer Acad Peds*.

Jensen PS, Arnold E, Swanson JM, et al. 3-Year Follow-up of the NIMH MTA Study. *J Am Acad Child Adolesc Psychiatry*, 46:8, August 2007.

Keenan K, Wakschlag LS. More than the terrible twos: the nature and severity of behavior problems in clinic-referred preschool children. *J Abnorm Child Psychol*. 2000;28(1):33-46.

Lahey BB, Pelham WE, Stein MA, et al. Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. *J Am Acad Child Adolesc Psychiatry*. 1998;37(7):695-702.

McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*; 2009;32(11):1089-1110

McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*. 2009;32(11):1089-1110

McGoey KE, DuPaul GJ, Haley E, Shelton TL. Parent and Teacher Ratings of Attention-Deficit/Hyperactivity Disorder in Preschool: The ADHD Rating Scale-IV Preschool Version. *J Psychopathol Behav Assess*. 2007;29(4):269-276

Medicaid.gov website. Accessed August 12, 2012. <http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Early-Periodic-Screening-Diagnosis-and-Treatment.html>.

Morley CP. Disparities in ADHD assessment, diagnosis, and treatment. *Int J Psychiatry Med*. 2010;40(4):383-9.

Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. *Pediatrics*. 2009;123(2):611-616

Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. *Pediatrics*. 2009;123(2):611-616

National Committee for Quality Assurance (NCQA). HEDIS® 2011: Healthcare Effectiveness Data and Information Set. Vol. 1 and 2, narrative. Washington (DC): National Committee for Quality Assurance (NCQA); 2010. various p.

- National Research Council. *Guidance for the National Healthcare Disparities Report* . Washington, DC: The National Academies Press, 2002.
- Pavuluri MN, Luk SL, McGee R. Parent reported preschool attention deficit hyperactivity: measurement and validity. *Eur Child Adolesc Psychiatry*. 1999;8(2):126-133
- Pelham W, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. *J Clin Child Adolesc Psychol*. 2008;37(1):184-214
- Pelham W, Wheeler T, Chronis A. Empirically supported psychological treatments for attention deficit hyperactivity disorder. *J Clin Child Psychol*. 1998;27(2):190-205
- Perrin JM, Friedman RA, Knilans TK, et al. Black Box Working Group, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. *Pediatrics*. 2008;122(2):451-453
- Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2007 Jul;46(7):894-921.
- Poblano A, Romero E. ECI-4 screening of attention deficit-hyperactivity disorder and comorbidity in Mexican preschool children: preliminary results. *Arq Neuropsiquiatr*. 2006;64(4):932-936
- Rothe EM. Considering cultural diversity in the management of ADHD in Hispanic patients. *J Natl Med Assoc* 2005;97(Suppl 10):17S-23S.
- Rowland, A S, Umbach D M, Stallone L, et al. Prevalence of Medication Treatment for Attention Deficit–Hyperactivity Disorder Among Elementary School Children in Johnston County, North Carolina.
- Scheffler R M, Hinshaw S P, Modrek S, et al. The Global Market for ADHD Medications.
- Scottish Intercollegiate Guidelines Network (SIGN). Management of attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2009 Oct. 52 p.(SIGN publication; no. 112).
- Sonuga-Barke E, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. *J Am Acad Child Adolesc Psychiatry*. 2001;40(4):402-408
- Sprafkin J, Volpe RJ, Gadow KD, Nolan EE, Kelly K. A DSM-IV-referenced screening instrument for preschool children: the Early Childhood Inventory-4. *J Am Acad Child Adolesc Psychiatry*. 2002;41(5):604-612

Stein R E K, McCue Horwitz S, Penfold R B, et al. Do Pediatricians Think They Should Care For Patients with New Morbidity? Results of the AAP Periodic Survey.

Subcommittee on Standardized Collection of Race/Ethnicity Data for Healthcare Quality Improvement, Institute of Medicine. "Front Matter." *Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement*. Washington, DC: The National Academies Press, 2009.

Swanson J, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. *J Am Acad Child Adolesc Psychiatry*; 2007;46(8):1015-1027.

Van Cleave J, Leslie LK. Approaching ADHD as a chronic condition: implications for long-term adherence. *J Psychosoc Nurs Ment Health Serv*. 2008;46(8):28-36.

Visser MS, Bitsko R H, Danielson M L, et al. Increasing Prevalence of Parent-Reported Attention Deficit/Hyperactivity Disorder Among Children; United States, 2003 and 2007. November 12, 2010 / 59(44);1439-1443SN.

Visser SN, Lesesne CA. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. *Pediatrics*. 2007;119(Suppl 1):S99-S106

Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention deficit hyperactivity disorder in adolescents: a review of the diagnosis, treatment and clinical implications. *Pediatrics*. 2005;115(6):1734-1746